NCT02367872View on ClinicalTrials.gov

Phase I Open-label Study to Evaluate Pharmacokinetics of TAK-272 in Participants With Renal or Hepatic Impairment

PHASE1CompletedINTERVENTIONAL

Enrollment

48

Participants

Timeline

Start Date

March 31, 2015

Primary Completion Date

June 30, 2016

Study Completion Date

June 30, 2016

Conditions

Renal ImpairmentHepatic Impairment

Interventions

DRUG

TAK-272

TAK-272 tablet

Trial Locations (4)

Unknown

Kurume

Moriya

Sagamihara

Shinagawa

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Takeda

INDUSTRY